{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:28Z","timestamp":1792813228569,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020992","name":"Caisse nationale de l'Assurance Maladie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bpobgyn.2022.102308","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T02:24:18Z","timestamp":1672194258000},"page":"102308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS)"],"prefix":"10.1016","volume":"88","author":[{"given":"M.","family":"Grynberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Cedrin-Durnerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Raguideau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Herquelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Verpillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Helwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Schwarze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Castello-Bridoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D'Hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bencha\u00efb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bpobgyn.2022.102308_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.fertnstert.2017.06.005","article-title":"The international glossary on infertility and fertility care, 2017","volume":"108","author":"Zegers-Hochschild","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.636038","article-title":"New human follitropin preparations: how glycan structural differences may affect biochemical and biological function and clinical effect","volume":"12","author":"Dias","year":"2021","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.bpobgyn.2022.102308_bib3","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1185\/030079905X75005","article-title":"Comparative characterisation of a commercial human chorionic gonadotrophin extracted from human urine with a commercial recombinant human chorionic gonadotrophin","volume":"21","author":"Bassett","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.102308_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1185\/030079902125001344","article-title":"Quantification of follicle stimulating hormone (follitropin alfa): is in\u00a0vivo bioassay still relevant in the recombinant age?","volume":"19","author":"Driebergen","year":"2003","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.102308_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1472-6483(10)60613-X","article-title":"Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin alpha)","volume":"13","author":"Lispi","year":"2006","journal-title":"Reprod Biomed Online"},{"issue":"4","key":"10.1016\/j.bpobgyn.2022.102308_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.6061\/clinics\/2014(04)10","article-title":"Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech","volume":"69","author":"Le\u00e3o","year":"2014","journal-title":"Clinics"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.fertnstert.2018.06.005","article-title":"Forty years of IVF","volume":"110","author":"Niederberger","year":"2018","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.102308_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/molehr\/2.5.371","article-title":"Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon)","volume":"2","author":"Olijve","year":"1996","journal-title":"Mol Hum Reprod"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.102308_bib9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1472-6483(10)60163-0","article-title":"Analytical identification of additional impurities in urinary-derived gonadotrophins","volume":"19","author":"Bassett","year":"2009","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.102308_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1472-6483(10)60937-6","article-title":"Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH","volume":"10","author":"Bassett","year":"2005","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fendo.2019.00429","article-title":"The development of gonadotropins for clinical use in the treatment of infertility","volume":"10","author":"Lunenfeld","year":"2019","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.102308_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","article-title":"A\u00a0randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer","volume":"97","author":"Devroey","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1477-7827-8-112","article-title":"Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis","volume":"8","author":"Lehert","year":"2010","journal-title":"Reprod Biol Endocrinol : RBE (Rev Bras Entomol)"},{"issue":"6","key":"10.1016\/j.bpobgyn.2022.102308_bib14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.rbmo.2012.02.009","article-title":"Array CGH analysis shows that aneuploidy is not related to the number of embryos generated","volume":"24","author":"Ata","year":"2012","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.102308_bib15","first-page":"370","article-title":"Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?","volume":"31","author":"Drakopoulos","year":"2016","journal-title":"Hum Reprod (Oxf)"},{"issue":"10","key":"10.1016\/j.bpobgyn.2022.102308_bib16","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1093\/humrep\/det303","article-title":"The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China","volume":"28","author":"Ji","year":"2013","journal-title":"Hum Reprod (Oxf)"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib17","article-title":"A\u00a0higher ovarian response after stimulation for IVF is related to a higher number of euploid embryos","volume":"2017","author":"Labarta","year":"2017","journal-title":"BioMed Res Int"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.102308_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/humrep\/dex334","article-title":"The number of oocytes retrieved during IVF: a balance between efficacy and safety","volume":"33","author":"Magnusson","year":"2018","journal-title":"Hum Reprod (Oxf)"},{"issue":"7","key":"10.1016\/j.bpobgyn.2022.102308_bib19","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum Reprod (Oxf)"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.102308_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00404-017-4503-9","article-title":"Association between the number of oocytes retrieved and cumulative live birth rate in women aged 35-40 years undergoing long GnRH agonist IVF\/ICSI cycles","volume":"296","author":"Zhou","year":"2017","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.102308_bib21","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI(\u2020)","volume":"2020","author":"Bosch","year":"2020","journal-title":"Human reproduction open"},{"issue":"4","key":"10.1016\/j.bpobgyn.2022.102308_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2018.04.039","article-title":"Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in\u00a0vitro fertilization\/intracytoplasmic sperm injection: a multicenter multinational analysis including \u223c15,000 women","volume":"110","author":"Polyzos","year":"2018","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib23","author":"EMA","year":"2014"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib24","series-title":"Biosimilar medicines: Overview amsterdam, The Netherlands","author":"EMA","year":"2022"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.102308_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12958-016-0167-8","article-title":"Biosimilar FSH preparations- are they identical twins or just siblings?","volume":"14","author":"Orvieto","year":"2016","journal-title":"Reprod Biol Endocrinol : RBE (Rev Bras Entomol)"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.102308_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rbmo.2017.03.020","article-title":"Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic","volume":"35","author":"de Mora","year":"2017","journal-title":"Reprod Biomed Online"},{"issue":"6","key":"10.1016\/j.bpobgyn.2022.102308_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40259-015-0147-0","article-title":"The diversity of biosimilar design and development: Implications for policies and stakeholders","volume":"29","author":"Grampp","year":"2015","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.bpobgyn.2022.102308_bib28","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.3390\/ijms23126762","article-title":"Comparative assessment of the structural features of originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilar preparations approved in non-European regions","volume":"23","author":"Manzi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.bpobgyn.2022.102308_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184139","article-title":"In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f)","volume":"12","author":"Mastrangeli","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.rbmo.2015.01.005","article-title":"A\u00a0multi-centre phase 3 study comparing efficacy and safety of Bemfola((R)) versus Gonal-f((R)) in women undergoing ovarian stimulation for IVF","volume":"30","author":"Rettenbacher","year":"2015","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12958-015-0135-8","article-title":"Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap(R) (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)","volume":"14","author":"Strowitzki","year":"2016","journal-title":"Reprod Biol Endocrinol : RBE (Rev Bras Entomol)"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib32","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4103\/0366-6999.232808","article-title":"Overall blastocyst quality, trophectoderm grade, and inner cell mass grade predict pregnancy outcome in euploid blastocyst transfer cycles","volume":"131","author":"Zhao","year":"2018","journal-title":"Chin Med J"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.102308_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12958-021-00727-y","article-title":"Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F\u00ae) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis","volume":"19","author":"Chua","year":"2021","journal-title":"Reprod Biol Endocrinol : RBE (Rev Bras Entomol)"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib34","series-title":"Biosimilar recombinant human FSH (Follitropin alpha) for controlled ovarian stimulation in ovulatory women undergone IVF\/ICSI cycles? A systematic review and meta-analysis","volume":"vol. 37","author":"Youssef","year":"2022"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.102308_bib35","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/humrep\/deac030","article-title":"Are we leaving money on the table in infertility RCTs? Trialists should statistically adjust for prespecified, prognostic covariates to increase power","volume":"37","author":"Wilkinson","year":"2022","journal-title":"Hum Reprod (Oxf)"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.102308_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.rbmo.2016.11.010","article-title":"'Model' versus 'everyday' patients: can randomized controlled trial data really be applied to the clinic?","volume":"34","author":"Hershkop","year":"2017","journal-title":"Reprod Biomed Online"},{"issue":"12","key":"10.1016\/j.bpobgyn.2022.102308_bib37","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/humrep\/del284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Andersen","year":"2006","journal-title":"Hum Reprod (Oxf)"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib38","first-page":"40","article-title":"Extended analyses of the German IVF registry (DIR): Andrological Aspects, medical-economical assumptions related to the shift from IVF to ICSI and stimulation with gonadotropins","volume":"7","author":"Bals-Pratsch","year":"2010","journal-title":"J\u00a0Reproduktionsmed Endokrinol"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib39","first-page":"196","volume":"17","author":"Blumenauer","year":"2020","journal-title":"J\u00a0Reproduktionsmed Endokrinol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.102308_bib40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12958-021-00768-3","article-title":"Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany","volume":"19","author":"B\u00fchler","year":"2021","journal-title":"Reprod Biol Endocrinol : RBE (Rev Bras Entomol)"},{"issue":"8","key":"10.1016\/j.bpobgyn.2022.102308_bib41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/09513590.2016.1153058","article-title":"Comparison between stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF with GnRH antagonist protocol","volume":"32","author":"Shavit","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib42","author":"Agence de la Biom\u00e9decine","year":"2020"},{"issue":"8","key":"10.1016\/j.bpobgyn.2022.102308_bib43","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 4","key":"10.1016\/j.bpobgyn.2022.102308_bib44","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d'information interr\u00e9gimes de l'Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Revue d'epidemiologie et de sante publique"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib45","series-title":"Public S","year":"2022"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib46","series-title":"European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal products applications Amsterdam","author":"EMA","year":"2019"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib47","series-title":"uct exclusivity for biological products filed under section 351(a) of the PHS act: guidance for industry Maryland","author":"FDA","year":"2014"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib48","series-title":"Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry Maryland","author":"FDA","year":"2015"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib49","series-title":"Questions and answers on biosimilar development and the BPCI act: guidance for industry Maryland, USA","author":"FDA","year":"2021"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib50","series-title":"Elonva: summary of product chracteristics amsterdam","author":"EMA","year":"2022"},{"issue":"7","key":"10.1016\/j.bpobgyn.2022.102308_bib51","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/jech.2004.029496","article-title":"Estimating causal effects from epidemiological data","volume":"60","author":"Hern\u00e1n","year":"2006","journal-title":"J\u00a0Epidemiol Community Health"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.102308_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00001648-200105000-00011","article-title":"Data, design, and background knowledge in etiologic inference","volume":"12","author":"Robins","year":"2001","journal-title":"Epidemiology"},{"issue":"9","key":"10.1016\/j.bpobgyn.2022.102308_bib53","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/humrep\/dey263","article-title":"Predicting the cumulative chance of live birth over multiple complete cycles of in\u00a0vitro fertilization: an external validation study","volume":"33","author":"Leijdekkers","year":"2018","journal-title":"Hum Reprod (Oxf)"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.102308_bib54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.fertnstert.2021.09.015","article-title":"Predicting personalized cumulative live birth following in\u00a0vitro fertilization","volume":"117","author":"McLernon","year":"2022","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.102308_bib55","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/humrep\/dez258","article-title":"A\u00a0systematic review of the quality of clinical prediction models in in\u00a0vitro fertilisation","volume":"35","author":"Ratna","year":"2020","journal-title":"Hum Reprod (Oxf)"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib56","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"issue":"25","key":"10.1016\/j.bpobgyn.2022.102308_bib57","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.bpobgyn.2022.102308_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40471-017-0131-y","article-title":"Propensity scores in pharmacoepidemiology: beyond the horizon","volume":"4","author":"Jackson","year":"2017","journal-title":"Current epidemiology reports"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib59","series-title":"Gonal-f product information The Netherlands","author":"EMA","year":"2022"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.102308_bib60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.AOG.0000196503.78126.62","article-title":"Ectopic pregnancy risk with assisted reproductive technology procedures","volume":"107","author":"Clayton","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2022.102308_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.632674","article-title":"Safety of Ovaleap\u00ae (follitropin alfa) in infertile women undergoing superovulation for assisted reproductive technologies: a multinational comparative, prospective cohort study","volume":"12","author":"Kaplan","year":"2021","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.bpobgyn.2022.102308_bib62","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1093\/humrep\/del278","article-title":"Perioperative and post-operative complications of transvaginal ultrasound-guided oocyte retrieval: prospective study of >1000 oocyte retrievals","volume":"21","author":"Ludwig","year":"2006","journal-title":"Hum Reprod (Oxf)"},{"issue":"12","key":"10.1016\/j.bpobgyn.2022.102308_bib63","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1007\/s12325-020-01512-w","article-title":"The frequency of ovarian hyperstimulation syndrome and thromboembolism with originator recombinant human follitropin alfa (GONAL-f) for medically assisted reproduction: a systematic review","volume":"37","author":"Velthuis","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.102308_bib64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/humupd\/dmn045","article-title":"The risk of monozygotic twins after assisted reproductive technology: a systematic review and meta-analysis","volume":"15","author":"Vitthala","year":"2009","journal-title":"Hum Reprod Update"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.102308_bib65","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/humrep\/deh078","article-title":"Incidence of spontaneous abortion among pregnancies produced by assisted reproductive technology","volume":"19","author":"Wang","year":"2004","journal-title":"Hum Reprod (Oxf)"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.102308_bib66","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10815-021-02077-5","article-title":"Fertility technologies and how to optimize laboratory performance to support the shortening of time to birth of a healthy singleton: a Delphi consensus","volume":"38","author":"Coticchio","year":"2021","journal-title":"J\u00a0Assist Reprod Genet"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693422001894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693422001894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:14:49Z","timestamp":1761498889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693422001894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":66,"alternative-id":["S1521693422001894"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.102308","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS)","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.102308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102308"}}